ASH 2022 | Prognostic impact of FLT3-ITD in older patients with AML
Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, highlights results from a retrospective study that assessed the prevalence of FLT3-ITD mutations in older patients with acute myeloid leukemia (AML) and evaluated whether FLT3-ITD+ is associated with an inferior prognosis in this age group. The findings indicated no difference in prognosis between FLT3-wild type and FLT3-ITD patients. Prof. Stone believes that the findings obtained from this study are likely due to the emergence of FLT3 inhibitors as well as the presence of co-mutations in many patients. With these results, Prof. Stone emphasizes that the prognostic significance of a FLT3-ITD mutation should be re-evaluated in older patients with AML. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Steering committee: AbbVie; DSMB: Aptevo, Epizyme, Syntrix, Takeda; Advisory board: AvenCell, Cellularity, CTI Pharma, GSK, Kura Onc, Rigel; Focus group: BerGenBio; Grand rounds: Jazz
